Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 36%
Sell 7%
Strong Sell 0%

Bulls say

Incyte's recent financial performance reflects strong revenue growth driven primarily by robust demand for Jakafi, which experienced a 10% year-over-year increase in paid demand across all indications. The firm has also seen significant advancement in its dermatology sector, with Opzelura achieving $188 million in revenue, surpassing expectations and benefiting from increased patient demand for atopic dermatitis and vitiligo treatments. Furthermore, Incyte has raised its full-year 2025 guidance to $4.23 billion - $4.32 billion, bolstered by increased revenue forecasts for Jakafi and other oncology products, showcasing the company's strong market position and potential for continued growth.

Bears say

Incyte faces several significant challenges that contribute to a negative outlook on its stock. Key risks include eroding pricing power for its leading drug, Jakafi, alongside poor performance from the earlier-stage pipeline, which may lead to disappointing outcomes for ongoing clinical trials. Additionally, potential disruptions from increased competition, reimbursement challenges, and safety concerns regarding marketed products further jeopardize the company's revenue and growth prospects.

Incyte (INCY) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 36% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 14 analysts, Incyte (INCY) has a Buy consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.